Journal article
ARID1A mutations in endometriosis-associated ovarian carcinomas
KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, MK McConechy, MS Anglesio, SE Kalloger, W Yang, A Heravi-Moussavi, R Giuliany, C Chow, J Fee, A Zayed, L Prentice, N Melnyk, G Turashvili, AD Delaney Show all
New England Journal of Medicine | Published : 2010
Abstract
BACKGROUND: Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis, but the molecular events involved in this transformation have not been described. METHODS: We sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWI-SNF chromatin remodeling complex. We sequenced ARID1A in an additional 210 ovarian carcinomas and a second ovarian clear-cell carcinoma cell line and measured BAF250a expression by means of immunohistochemical analysis in an additional 455..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Supported by grants from the British Columbia (BC) Cancer Foundation and the Vancouver General Hospital (VGH)-University of British Columbia Hospital Foundation (to the OvCaRe ovarian cancer research team in Vancouver) and the Canadian Institutes of Health Research (CIHR). The Michael Smith Genome Sciences Centre (MSGSC), with which many of the authors are affiliated, is funded by Genome Canada, and OvCaRe and the MSGSC are also funded by the Michael Smith Foundation for Health Research (MSFHR). Salary support is provided by MSFHR to Drs. Shah, Marra, Jones, and Huntsman; by the CIHR Training Program for Clinician Scientists in Molecular Oncologic Pathology to Drs. Al-Agha and Turashvili (STP-53912); by the CIHR Bioinformatics Training Program for Health Research to Mr. McPherson and Mr. Ha; by the Canadian Breast Cancer Foundation to Dr. Shah; and a Canada Research Chair in Molecular Oncology to Dr. Aparicio. The Genetic Pathology Evaluation Centre, which constructed the tissue microarrays, has received nondirected research grants from Sanofi-Aventis, Canada. The contributing tumor banks were supported by OvCaRe and Ovarian Cancer Canada (VGH, Banque de Tissus et de Donnees of the Reseau de Recherche sur le Cancer of the Fonds de la Recherche en Sante du Quebec, affiliated with the Canadian Tumor Repository Network), and by a grant (DAMD17-O1-1-0729) from the U.S. Army Medical Research and Materiel Command; grants from the Cancer Council Tasmania, the Cancer Foundation of Western Australia, and the National Health and Medical Research Council of Australia to AOCS; and grants from the National Cancer Institute, National Institutes of Health (RO1CA103937 and RO1CA129080).